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background:  In prior studies in pigs, ivabradine reduced infarct size even when given only at reperfusion and in the absence of heart rate 
reduction. The mechanism of such non-heart rate-related cardioprotection is unknown.
methods:  Anesthetized C57Bl/6J mice were pretreated ± ivabradine (1.7 mg/kg i.v.) before 30 min coronary occlusion and 120 min 
reperfusion (± left atrial pacing). Infarct size was quantified by TTC staining (n=6). Ventricular cardiomyocytes were enzymatically isolated 
from mouse hearts (n=9). Simulated ischemia (I) was induced for 60 min (hypoxia, pH 6.5, 310 mOsm/l) and followed by 5 min reperfusion 
(R, normoxia, pH 7.4, 250 mOsm/l) ±3 µmol/l ivabradine. After simulated I/R, cellular viability was quantified (>200 cells/per preparation), 
and extracellular reactive oxygen species (ROS) formation was detected. Mitochondria were isolated from mouse hearts by differential 
centrifugation. Simulated I/R (6 min hypoxia/3 min normoxia) was induced in glutamate/malate- and ADP-containing buffer ±3 µmol/l 
ivabradine at 30°C. After simulated I/R, mitochondrial complex I respiration (n=32, preparations), mitochondrial ROS formation (n=9) and 
ATP concentration (n=15) were quantified.
Results:  Ivabradine reduced infarct size from 39±5% to 17±4% (p<0.05) of the area at risk, and this benefit remained with atrial 
pacing (20±5%; p<0.05). Cardiomyocyte viability after simulated I/R was better preserved with ivabradine (10±1 vs. 25±2%; p< 0.01). 
Cardiomyocyte ROS formation was reduced with ivabradine after simulated I (14±3 vs. 9±3 µmol H2O2/100 µg protein; p<0.05) and 
R (29±4 vs. 17±4 nmol H2O2/100 µg protein; p<0.001), respectively. Mitochondrial complex I respiration was not affected, but ROS 
formation was reduced (144±12 vs. 122±12 nmol H2O2/100 µg protein; p=0.01), and the ATP concentration was increased (148±20 vs. 
181±21µmol/l; p=0.01) by ivabradine.
conclusion:  Ivabradine reduces infarct size with or without heart rate reduction and, it improves ventricular cardiomyocyte viability, 
possibly by reduced mitochondrial ROS formation and increased ATP production.
